A Phase II Single-Arm Prospective Clinical Study of Adebrelimab Combined with Chemotherapy With or Without Bevacizumab as First-Line Treatment for Recurrent/Persistent/Metastatic Cervical Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500107989

Enrollment

Unknown

Registered

2025-08-21

Start date

2025-08-26

Completion date

Unknown

Last updated

2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent/Persistent/Metastatic Cervical Cancer

Interventions

Recurrent/Persistent/Metastatic Cervical Cancer:Adebrelimab combined with chemotherapy with or without bevacizumab

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Histologically confirmed recurrent/persistent/metastatic cervical cancer (squamous cell carcinoma/adenocarcinoma/adenosquamous carcinoma); 2.Not eligible for curative surgery/radiotherapy; 3.No prior systemic therapy for recurrent/metastatic disease; 4.PD-L1 expression unrestricted (but status must be documented); 5.ECOG PS 0-2 with life expectancy >= 6 months; 6.At least one measurable lesion per RECIST v1.1; 7.Patients voluntarily signed informed consent forms;

Exclusion criteria

Exclusion criteria: 1.Uncontrolled hypertension and cardiac dysfunction (NYHA class III-IV); 2.Myocardial infarction or stroke within the past 6 months; 3.Active infection, immunodeficiency, or requirement for long-term immunosuppressive therapy; 4.Severe hepatic/renal dysfunction (ALT/AST >3×ULN, Cr >1.5×ULN) and other risk factors; 5.Major surgery within 6 weeks; 6.Hypersensitivity or contraindications to any component of the investigational drug;

Design outcomes

Primary

Measure	Time frame
Objective Response Rate(ORR);	—

Countries

China

Contacts

Public ContactRenliang Fan

First Hospital Of Nanping

523221402@qq.com+86 599 8605951

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026